HASBROUCK HEIGHTS, N.J., August 8 /CNW/ - Nymox Pharmaceutical Corporation (NASDAQ: NYMX - News) holds U.S. and global patent rights for the use of statin drugs for the prevention and treatment of Alzheimer’s disease (AD), including for patients at risk for AD because of vascular-related risk factors or disease. Three newly published peer-review studies from the Karolinska Institute in Sweden and the Sun Health Research Institute in Arizona have provided new clinical trial and research data supporting statin use for Alzheimer’s and elucidating how the statin drugs are believed to produce these beneficial effects on the brain. In addition, a widely circulated report in yesterday’s Washington Times (August 7, 2006) quotes experts referring to the promise of statin drugs for Alzheimer’s patients.
